Privately held Jaguar LAA acquired the heart device technology with backing from Santé Ventures.
Johnson & Johnson has sold assets related to its Laminar program to Jaguar LAA, Inc., a newly formed, privately held medical device company based in Santa Rosa, California.
The Laminar program focuses on left atrial appendage closure for patients with non-valvular atrial fibrillation to reduce stroke risk. The technology uses a catheter-based rotational approach designed to leave minimal device exposure inside the left atrium.
Jaguar was formed in partnership with healthcare investment firm Santé Ventures and members of the Laminar management team. Santé Ventures, which manages more than $1 billion in capital, led the formation, financing, and asset acquisition alongside management and other investors. Financial terms of the transaction were not disclosed.
Newsletter
Markets in your inbox, weekly
LATAM-focused analysis, investing ideas, and the week in finance.